NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer
| ISRCTN | ISRCTN17428671 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17428671 |
| EudraCT/CTIS number | 2017-005015-13 |
| ClinicalTrials.gov number | NCT03721757 |
| Secondary identifying numbers | 37191 |
- Submission date
- 02/07/2018
- Registration date
- 06/07/2018
- Last edited
- 11/01/2021
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English Summary
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-of-nivolumab-and-usual-treatment-for-mouth-cancer-nico-ca209-891 (added 11/06/2019)
Contact information
Mr Robert Hanson
Scientific
Scientific
Cancer Research UK Liverpool Cancer Trials Unit
1st Floor, MerseyBio
Crown Street
Liverpool
L69 7ZB
United Kingdom
 ORCID ID |
0000-0002-5084-9622 |
|---|---|
| Phone | +44 (0)151 794 8852 |
| r.hanson@liverpool.ac.uk |
Study information
| Study design | Non-randomised; Interventional; Design type: Treatment, Drug, Radiotherapy, Immunotherapy, Surgery |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer |
| Study acronym | NICO - CA209-891 |
| Study hypothesis | Mouth cancer is usually treated with surgery, often followed by radiation therapy with or without chemotherapy. Unfortunately despite this treatment, it recurs or spreads in about half of patients. Recently, a drug called nivolumab which is given into a vein via a drip, has been shown to be of benefit where the cancer has spread and worsened following treatment with chemotherapy. This drug stimulates the immune system and when it works, often does so for a long period of time. In this trial the aim is to use this drug to reduce the chances of the cancer coming back after surgery and radiotherapy. The study will assess if this treatment leads to a reduction in the cancer recurring. |
| Ethics approval(s) | London - Harrow Research Ethics Committee 18/LO/0368; First MREC approval date 18/05/2018 |
| Condition | Mouth cancer |
| Intervention | This is a non-randomised phase II study of nivolumab in high risk oral cavity cancer for whom resection is the primary treatment. Patients will be assigned to one of two cohorts based on pathological findings following surgery. Following initial biopsy and confirmation of eligibility, patients will be enrolled and treated with a single dose of nivolumab (240 mg flat dose), followed by surgery to remove their tumour within 1-2 weeks. Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with high risk criteria (extracapsular spread, involved margins) as determined on pathological review following surgery will be assigned to chemoradiotherapy. A further single dose of nivolumab (240 mg flat dose) will be given between surgery and commencement of chemoradiotherapy or radiotherapy (1-2 weeks prior). Radiotherapy will be administered over 30 fractions i.e. over 30 days (Monday to Friday for 6 consecutive weeks). Patients receiving chemoradiotherapy will receive concomitant Cisplatin (100mg/m2) on day 1 and day 21 of radiotherapy treatment. Following completion of chemo/radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals. On completion of chemoradiotherapy or radiotherapy, all patients will have imaging of the head & neck and chest using CT and/or MRI. Further scans will be performed at 8 and 12 months post surgery, with an end of study visit after the last scan. Patients will then be followed up for survival until the final study definition is reached. |
| Intervention type | Mixed |
| Primary outcome measure | 1. 1-year disease free survival ≥ 75% in high-risk population. The endpoint is disease recurrence at 12 months measured as a 1 for patients who have disease recurrence (or death by any cause) and 0 for those that do not 2. Feasibility of recruitment to both cohorts, predominantly assessed using the recruitment rate as the endpoint of interest measured as the number of patients/site/month |
| Secondary outcome measures | 1. Safety, measured and categorised based on CTCAE (version 4). Interest will predominantly be on the number of grade 3/4 adverse events 2. Time to recurrence, measured as the time from surgery until disease recurrence or death by any cause 3. Overall survival, measured as the time from registration until death by any cause 4. Quality of life, measured using Quality of Life Questionnaire–Core 30 module (QLQ-C30) and the head-and-neck–specific module (QLQ-H&N35) at: 4.1. Prior to surgery and initial nivolumab treatment 4.2. Post surgery but pre-radiotherapy/chemoradiotherapy 4.3. First administration of nivolumab post radiotherapy/chemoradiotherapy 4.4. Third administration of nivolumab post radiotherapy/chemoradiotherapy 4.5. Sixth administration of nivolumab post radiotherapy/chemoradiotherapy 4.6. End of study treatment/safety visit 5. Surgical complications: infection rate, length of hospital admission, free flap failure, perioperative (30-day) mortality |
| Overall study start date | 01/12/2017 |
| Overall study end date | 01/09/2021 |
| Reason abandoned (if study stopped) | Participant recruitment issue |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 120; UK Sample Size: 120 |
| Total final enrolment | 23 |
| Participant inclusion criteria | 1. Signed, written informed consent 2. Subjects must be willing and able to comply with scheduled visits and procedures 3. Histologically confirmed squamous cell carcinoma of the oral cavity (oral tongue (anterior 2/3), gingiva/alveolus, floor of mouth, buccal sulcus, retromolar trigone, and hard palate as defined by ICD-10 codes) 4. Subjects willing to have a fresh biopsy performed, or archival tissue available from diagnostic biopsy meeting requirements set out in laboratory manual 5. Clinically and/or radiologically staged as T1-4 N1-3 or any T3-4 N0 (unless T4 on the basis of bone invasion only). Staging based upon the AJCC/UICC TNM 8th Edition 6. Surgery planned as primary treatment modality with patients fit for major resection ± reconstruction surgical procedure 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 8. 18 years or over at time of provision of consent for trial inclusion 9. Screening laboratory values must meet the following criteria: WBC ≥ 2000/µL Neutrophils ≥ 1500/uL Platelets ≥ 100x103/uL Hemoglobin ≥ 9.0 g/dL Serum creatinine ≤1.5 x ULN or calculated creatinine clearance > 40 mL/min (using the Cockcroft-Gault formula) AST ≤ 3.0 x ULN ALT ≤ 3.0 x ULN Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome who must have a total bilirubin level of < 3.0x ULN) 10. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug 11. Women must not be breastfeeding 12. WOCBP must agree to follow instructions for method(s) of contraception for a period of 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo approximately five half-lives. WOCBP randomized/assigned to receive nivolumab should use an adequate method to avoid pregnancy for 5 months (30 days plus the time required for nivolumab to undergo approximately five half-lives) after the last dose of investigational drug 13. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo approximately five half-lives 14. Males randomized to receive nivolumab who are sexually active with WOCBP must continue contraception for 7 months (90 days plus the time required for nivolumab to undergo approximately five half-lives) after the last dose of investigational drug. Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However, they must still undergo pregnancy testing as described in these sections. Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception which have a failure rate of < 1% when used consistently and correctly |
| Participant exclusion criteria | 1. Tumours staged as T4 on the basis of bone invasion only and in the absence of nodal metastases 2. Distant metastases detected, or suspected on imaging 3. Unfit for chemoradiotherapy, due to comorbidity 4. Previous malignancy requiring treatment within the last 3 years (with the exception of non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, oesophageal endometrial, cervical/dysplasia, melanoma, or breast). Prior head and neck cancer within the last three years is allowed if the tumour was treated with surgery only, and did not require radiotherapy 5. Prior head and neck radiotherapy 6. On immunosuppressive medication (including steroids at dose equivalent to prednisolone > 10mg/day unless used as replacement therapy) 7. Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, lichen planus or other conditions not expected to recur in the absence of an external trigger are permitted to enrol 8. Known human immunodeficiency virus (HIV) or viral hepatitis infection 9. Women who are pregnant or breastfeeding 10. Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results |
| Recruitment start date | 01/09/2018 |
| Recruitment end date | 01/03/2020 |
Locations
Countries of recruitment
- England
- Scotland
- United Kingdom
- Wales
Study participating centres
Clatterbridge Cancer Centre (lead centre)
Clatterbridge Road
Bebington
Wirral
CH63 4JY
United Kingdom
Bebington
Wirral
CH63 4JY
United Kingdom
University Hospital Aintree
Fazakerley Hospital
Lower Lane
Liverpool
L9 7AL
United Kingdom
Lower Lane
Liverpool
L9 7AL
United Kingdom
NHS Greater Glasgow and Clyde
Beatson West of Scotland Cancer Centre
1055 Great Western Road
Glasgow
G12 0XH
United Kingdom
1055 Great Western Road
Glasgow
G12 0XH
United Kingdom
University College London Hospital
250 Euston Road
London
NW1 2PG
United Kingdom
London
NW1 2PG
United Kingdom
The Christie Hospital
550 Wilmslow Road
Withington
Manchester
M20 4BX
United Kingdom
Withington
Manchester
M20 4BX
United Kingdom
Queen Victoria Hospital
Holtye Road
East Grinstead
RH19 3DZ
United Kingdom
East Grinstead
RH19 3DZ
United Kingdom
Northern General Hospital
Sheffield Teaching Hospitals NHS Foundation Trust
Herries Road
Sheffield
S5 7AU
United Kingdom
Herries Road
Sheffield
S5 7AU
United Kingdom
Velindre Cancer Centre
Velindre Road
Cardiff
CF14 2TL
United Kingdom
Cardiff
CF14 2TL
United Kingdom
Royal Sussex County Hospital
Eastern Road
Brighton
BN2 5BE
United Kingdom
Brighton
BN2 5BE
United Kingdom
Royal Surrey County Hospital
Egerton Road
Guildford
GU2 7XX
United Kingdom
Guildford
GU2 7XX
United Kingdom
Sponsor information
The Clatterbridge Cancer Centre NHS Foundation Trust
Hospital/treatment centre
Hospital/treatment centre
Clatterbridge Road
Bebington
Wirral
CH63 4JY
England
United Kingdom
| Phone | +44 (0)151 482 7804 ext 4740 |
|---|---|
| Jennifer.almond@nhs.net | |
"ROR" |
https://ror.org/05gcq4j10 |
Funders
Funder type
Industry
Bristol-Myers Squibb International Corporation; Grant Codes: CA209-891
Government organisation / For-profit companies (industry)
Government organisation / For-profit companies (industry)
- Alternative name(s)
- Bristol-Myers Squibb Company, BMS
- Location
- United States of America
Results and Publications
| Intention to publish date | 01/09/2022 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | Additional documents will not be publicly available but requests for them will be considered upon receipt of an emailed request to the NICO Trial Coordinator. Planned publication of the study results in a high impact peer reviewed journal. |
| IPD sharing plan | The data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
11/01/2021: The trial was stopped due to participant recruitment issues. The total final enrolment number was added.
07/04/2020: Due to current public health guidance, recruitment for this study has been paused.
14/02/2020: ClinicalTrials.gov number added.
11/06/2019: Cancer Research UK lay summary link added to plain English summary field.
05/04/2019: Internal review.
22/03/2019: The condition was updated from "Specialty: Cancer, Primary sub-specialty: Head and Neck Cancer; UKCRC code/ Disease: Cancer and neoplasms/ Malignant neoplasms of lip, oral cavity and pharynx" to "mouth cancer".
05/03/2019: Internal review.
